-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec publishes company presentation outlining drug discovery strategy and outlook

PUBT·06/16/2026 19:26:46
Listen to the news
Evotec publishes company presentation outlining drug discovery strategy and outlook
  • Evotec outlined a mid-term plan built on faster-than-market growth, operational cost cuts, higher-margin biologics monetization, and larger milestone and royalty income.
  • Cost-out program targets EUR 60+ million in 2025, including a roughly 600 FTE reduction in D&PD from March 2024 to June 2025.
  • Just Evotec Biologics shift toward an asset-lighter model centers on a signed sale of the Toulouse J.POD site to Sandoz.
  • Deal terms include an upfront payment of about USD 350 million in 2025, revenue commitments of more than USD 300 million for 2026-2028, and royalties beyond 2028.
  • Asset pipeline milestone and royalty potential guided at more than EUR 500 million through 2028, with upside to more than EUR 1.2 billion by 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.